SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Nanotech Stocks to Watch -- Ignore unavailable to you. Want to Upgrade?


To: RikRichter who wrote (836)2/15/2005 4:12:18 PM
From: AV8R  Respond to of 1411
 
****************************
Forbes Wolfe Nanotech Report
Nanosphere Alert
****************************

Dear Subscriber,

In an unexpected announcement yesterday, NVE-licensee Cypress
said it intends to divest its Silicon Magnetic Systems (SMS)
subsidiary, founded to commercialize MRAM. While CY recently
announced successful MRAM sampling with several of its clients,
the company expressed doubts about MRAM's ability to serve as
a economically-viable replacement to discrete, commodity-like
SRAM memory.

While this announcement is a net-negative for NVE, it by no
means signals the death knell for the company or the future of
MRAM. NVE-licensee Motorola's [MOT] chip spin-off Freescale
[FSL], Toshiba and NEC [NIPNY] are all focused on
commercializing embedded-MRAM for high-end applications.
Motorola was sampling 4Mb MRAM chips with select clients at the
end of 2004. With Cypress, NVE has proved its MRAM technology
can serve as the basis for a fully-functional product. According
to Cypress CEO T.J. Rodgers said, "After a three-year effort,
Cypress sampled fully functional MRAMs to seven key OEM
customers in January. Three of those customers are still in the
validation phase of their assessment and four of them have
already confirmed with us that they have found the product fully
functional, as we announced in our quarterly earnings conference
call on January 27."

The Cypress announcement places an even higher priority on NVE's
ability to sign licensing deals in the next year. In 2005, NVE
must sign new licensing deals with Freescale (today planning to
operate under have-made rights granted by Motorola until the end
of 2005) and whatever corporation buys CY's MRAM unit. There are
significant risks, but we contend there is far greater upside.
The Cypress deal in particular was a unique technology-sharing
agreement, and any new agreement could become a far more
lucrative royalty-bearing deal. Motorola's royalty agreement with
NVE (estimated at 1%) is generally perceived as below market,
and a new FSL deal could come at a higher rate. While the CY
news complicates the NVE-story, the company is healthy and
profitable with adequate cash reserves to see it through any
delays in MRAM development. With a market cap of just north of
$100 million, NVE Corporation remains an extremely attractive
investment opportunity. We maintain our Buy rating.



To: RikRichter who wrote (836)3/1/2005 4:15:30 AM
From: Postman  Read Replies (1) | Respond to of 1411
 
This is great stuff- especially the medicinal applications-

Any conferences coming to Toronto?